Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 18, 2016. The document serves as a transaction notification regarding a Person Closely Associated (PCA) with a Principal Director, Manager, or Representative (PDMR), rather than a periodic financial report.
Key Financial Metrics
The filing does not provide company-wide financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to a specific individual transaction:
- Transaction Price: £16.34 per share
- Transaction Volume: 56 Ordinary Shares
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882)
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a single acquisition of shares by Mr. J P Witty (PCA of CEO Sir Andrew Witty) on July 15, 2016, executed on the London Stock Exchange.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transaction was an acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on July 14, 2016, on shares held within an Individual Savings Account (ISA).
Investor Verification Points
- Verify the identity of Mr. J P Witty as the PCA of CEO Sir Andrew Witty.
- Confirm the transaction date of July 15, 2016, and the execution venue (London Stock Exchange).
- Note that this filing does not reflect broader company performance; refer to Form 20-F for comprehensive financial data.